ImmunityBio shares are trading higher after Piper Sandler maintained a Neutral rating on the stock and raised its price target from $5 to $6.
Portfolio Pulse from Benzinga Newsdesk
ImmunityBio's stock price increased following Piper Sandler's decision to maintain a Neutral rating while raising its price target from $5 to $6.
April 29, 2024 | 11:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunityBio's stock price is likely to experience short-term positive momentum due to Piper Sandler's upgraded price target from $5 to $6, despite maintaining a Neutral rating.
The increase in ImmunityBio's price target by a reputable financial services firm like Piper Sandler can lead to positive investor sentiment, potentially driving up the stock price in the short term. Although the rating remains Neutral, the raised target suggests an improved outlook on the company's valuation, which can attract investor interest and impact the stock positively.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90